ArticleFunctional & integrative genomics2026

Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer.

Debolina Chakraborty et al.PubMed ↗Publisher ↗

No numbers read from the abstract.